SUPRIYA Stock Overview
Engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
My Notes
Capture your thoughts, links and company narrative
Supriya Lifescience Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹729.80 |
| 52 Week High | ₹835.20 |
| 52 Week Low | ₹275.65 |
| Beta | 0.21 |
| 1 Month Change | 5.71% |
| 3 Month Change | 15.65% |
| 1 Year Change | 145.68% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 86.72% |
Recent News & Updates
Recent updates
Supriya Lifescience Limited (NSE:SUPRIYA) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Nov 07
Supriya Lifescience (NSE:SUPRIYA) Has Announced That It Will Be Increasing Its Dividend To ₹0.80
Sep 08We Think You Should Be Aware Of Some Concerning Factors In Supriya Lifescience's (NSE:SUPRIYA) Earnings
Jun 05Little Excitement Around Supriya Lifescience Limited's (NSE:SUPRIYA) Earnings
May 10Lacklustre Performance Is Driving Supriya Lifescience Limited's (NSE:SUPRIYA) Low P/E
Feb 09Supriya Lifescience's (NSE:SUPRIYA) Shareholders May Want To Dig Deeper Than Statutory Profit
May 28Market Cool On Supriya Lifescience Limited's (NSE:SUPRIYA) Earnings Pushing Shares 27% Lower
May 07Shareholder Returns
| SUPRIYA | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -1.1% | 1.8% | -2.1% |
| 1Y | 145.7% | 43.7% | 22.5% |
Return vs Industry: SUPRIYA exceeded the Indian Pharmaceuticals industry which returned 43.7% over the past year.
Return vs Market: SUPRIYA exceeded the Indian Market which returned 22.5% over the past year.
Price Volatility
| SUPRIYA volatility | |
|---|---|
| SUPRIYA Average Weekly Movement | 7.9% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: SUPRIYA's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: SUPRIYA's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 448 | n/a | www.supriyalifescience.com |
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in anti-histamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, anti-malarial products, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products.
Supriya Lifescience Limited Fundamentals Summary
| SUPRIYA fundamental statistics | |
|---|---|
| Market cap | ₹61.54b |
| Earnings (TTM) | ₹1.58b |
| Revenue (TTM) | ₹6.25b |
37.3x
P/E Ratio9.4x
P/S RatioIs SUPRIYA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SUPRIYA income statement (TTM) | |
|---|---|
| Revenue | ₹6.25b |
| Cost of Revenue | ₹2.18b |
| Gross Profit | ₹4.07b |
| Other Expenses | ₹2.50b |
| Earnings | ₹1.58b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 19.57 |
| Gross Margin | 65.13% |
| Net Profit Margin | 25.20% |
| Debt/Equity Ratio | 0% |
How did SUPRIYA perform over the long term?
See historical performance and comparisonDividends
0.1%
Current Dividend Yield4%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 13:43 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Supriya Lifescience Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | K.R. Choksey Shares & Securities Private Ltd. |